384 related articles for article (PubMed ID: 2648225)
1. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
[TBL] [Abstract][Full Text] [Related]
2. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
3. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
4. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
Geyer H; Schwörer D; Pfleiderer A
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
[TBL] [Abstract][Full Text] [Related]
6. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma.
Tomás C; Risteli J; Risteli L; Vuori J; Kauppila A
Obstet Gynecol; 1991 Apr; 77(4):566-72. PubMed ID: 2002979
[TBL] [Abstract][Full Text] [Related]
7. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract][Full Text] [Related]
8. [Determination of the SCC antigen in the serum of patients with cervical cancer].
Crombach G; Würz H; Bolte A
Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):439-45. PubMed ID: 3623046
[TBL] [Abstract][Full Text] [Related]
9. [A clinical study on CA 15-3, CEA, SCC-Ag in patients with squamous cell carcinoma of the lung].
Moriya H; Suzuki S; Aizumi J; Kimura K; Urabe S; Higuci Y; Hoshi K
Rinsho Hoshasen; 1989 Jan; 34(1):63-6. PubMed ID: 2724610
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
11. [Experiences with the squamous cell carcinoma antigen, a new tumor marker for cancer of the uterine cervix].
Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H
Geburtshilfe Frauenheilkd; 1989 Jul; 49(7):625-9. PubMed ID: 2777050
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers in uterine cancers].
Fukasawa I; Kousaka N; Kun Z; Inaba N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
[TBL] [Abstract][Full Text] [Related]
14. [The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H
Geburtshilfe Frauenheilkd; 1989 Dec; 49(12):1050-5. PubMed ID: 2693187
[TBL] [Abstract][Full Text] [Related]
15. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix.
Bolli JA; Doering DL; Bosscher JR; Day TG; Rao CV; Owens K; Kelly B; Goldsmith J
Gynecol Oncol; 1994 Nov; 55(2):169-73. PubMed ID: 7959279
[TBL] [Abstract][Full Text] [Related]
16. [The monitoring of gynecological radiotherapy using serial tumor marker determinations].
Wagner RK; Atzinger A; Breit A
Strahlenther Onkol; 1990 Jul; 166(7):446-52. PubMed ID: 2200151
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
19. [Impact of squamous cell carcinoma antigen in patients with recurrent squamous cell carcinoma of the uterine cervix].
Ma SK; Wu LY; Sun YC; Li B; Zhang HT
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):13-7. PubMed ID: 18366925
[TBL] [Abstract][Full Text] [Related]
20. Monitoring endometrial adenocarcinoma with a four tumor marker combination. CA 125, squamous cell carcinoma antigen, CA 19.9 and CA 15.3.
Matorras R; Rodríguez-Escuderoi FJ; Diez J; Genollá J; Cruz Fombellida J; Ruibal A
Acta Obstet Gynecol Scand; 1992 Aug; 71(6):458-64. PubMed ID: 1326844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
